AG-EE 623 ZW
Categoria
AG-EE 623 ZW Marchi, AG-EE 623 ZW Analoghi
AG-EE 623 ZW Marchi miscela
AG-EE 623 ZW Formula chimica
C27H36N2O4
AG-EE 623 ZW RX link
http://www.rxlist.com/cgi/generic/prandin.htm
AG-EE 623 ZW FDA foglio
AG-EE 623 ZW DMS (foglio di materiale di sicurezza)
AG-EE 623 ZW Sintesi di riferimento
W. Grell et al. Int. PCT. pat. Appl. WO 93 00337
AG-EE 623 ZW Peso molecolare
452.586 g/mol
AG-EE 623 ZW Temperatura di fusione
130-131 oC
AG-EE 623 ZW H2O Solubilita
Nessuna informazione disponibile
AG-EE 623 ZW Stato
Solid
AG-EE 623 ZW LogP
5.798
AG-EE 623 ZW Forme di dosaggio
Compressa
AG-EE 623 ZW Indicazione
Per il trattamento del diabete mellito di tipo II.
AG-EE 623 ZW Farmacologia
La repaglinide è un orale di glucosio nel sangue farmaco che riduce della classe meglitinide utilizzato nella gestione del diabete di tipo 2 (noto anche come diabete non insulino-dipendente o NIDDM mellito). Repaglinide abbassa i livelli di glucosio nel sangue stimolando il rilascio di insulina dal pancreas. Questa azione è dipende dal funzionamento delle cellule beta nelle isole pancreatiche. Rilascio di insulina glucosio-dipendente è e diminuisce a basse concentrazioni di glucosio.
AG-EE 623 ZW Assorbimento
Rapido (biodisponibilità è del 56%)
AG-EE 623 ZW Tossicita
LD50> 1 g / kg (ratto) (W. Grell)
AG-EE 623 ZW Informazioni paziente
PATIENT INFORMATION
Patients should be informed of the potential risks and advantages of Repaglinide (PRANDIN) and of alternative modes of therapy. They should also be informed about the importance of adherence to dietary instructions, of a regular exercise program, and of regular testing of blood glucose and HbA1c. The risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development and concomitant administration of other glucose-lowering drugs should be explained to patients and responsible family members. Primary and secondary failure should also be explained.
Patients should be instructed to take Repaglinide before meals (2, 3, or 4 times a day preprandially). Doses are usually taken within 15 minutes of the meal but time may vary from immediately preceding the meal to as long as 30 minutes before the meal. Patients who skip a meal (or add an extra meal) should be instructed to skip (or add) a dose for that meal.
Patients should be informed of the potential risks and advantages of Repaglinide (PRANDIN) and of alternative modes of therapy. They should also be informed about the importance of adherence to dietary instructions, of a regular exercise program, and of regular testing of blood glucose and HbA1c. The risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development and concomitant administration of other glucose-lowering drugs should be explained to patients and responsible family members. Primary and secondary failure should also be explained.
Patients should be instructed to take Repaglinide before meals (2, 3, or 4 times a day preprandially). Doses are usually taken within 15 minutes of the meal but time may vary from immediately preceding the meal to as long as 30 minutes before the meal. Patients who skip a meal (or add an extra meal) should be instructed to skip (or add) a dose for that meal.
AG-EE 623 ZW Atto interessato organismi
Gli esseri umani e altri mammiferi
